Vaccine World Summit India 2015 by 丽清

Pl at i numSponsor

Gol dSponsor

Assoc i at eSponsor

L unc ht i meWor kshopSponsor s

Exhi bi t or s

Conference Proceedings

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

CONTENTS The IMAPAC Difference

Section 1

Welcome About IMAPAC, Imagine Your Impact Speed Networking Media Partners Outside of Conference Hours

Conference Programme Day 1

Section 2

Conference Programme Day 2

Section 3

Conference Evaluation

Green Form

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

IMAPAC welcomes you to VACCINE WORLD SUMMIT INDIA 2015 WANG Ting Ting General Manager Tel: +65 6493 1880 Email: tingting.wang@imapac.com

Romilly SINCLAIR Creative Director Tel: +65 6493 2095 Email: romilly.sinclair@imapac.com

Natasha JIANDANI Project Director Tel: +65 6493 1881 Email: natasha.jiandani@imapac.com

Mathew ORIEL Creative Director Tel: +65 6493 1601 Email: mathew.oriel@imapac.com

Talha FAZAL Business Development Consultant Tel: +65 6493 1870 Email: tahal.fazal@imapac.com

Cecilia WONG Senior Marketing & Operations Manager Tel: +65 6493 2093 Email: cecilia.wong@imapac.com

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

About IMAPAC - Creating Conferences with A Cause IMAPAC is a social enterprise that is on an unrelenting mission to strive and make a difference to businesses of today. We believe businesses are not only meant to do well, but also to do good. We want you to find business opportunities at our conferences as well something good to aim for. IMAPAC’s conferences are when you join other organizations such as governments, NGOs, businesses, academics and other stakeholders who standing up collectively to make a difference, to attest to the fact that businesses can and do make a positive impact to the world we are living in.

Just Imagine your Impact When you speak at an IMAPAC conference, not only does the industry hear you, the world does too – via IMAPAC TV broadcast FREE to everyone around the globe. When participate at an IMAPAC conference, not only does your knowledge and contact book get extended, a child from a developing country gets to go to school for year.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Speed Networking @ IMAPAC - Creating Conferences with A Cause We have an exciting networking activity planned for you during the conference. Here’s how the IMAPAC speed networking session works: 1.

When you enter the networking area, make your way to any one of the bistro tables. Each table should be made up of a maximum of 8 - 10 people.

You should have already picked up an envelope earlier during registration. Your envelope contains either a Blue or Green card. * Please request at the registration should you not receive it.

At the sound of the bell, your networking time with others at your current table begins. You will have about 4-5 minutes.

Then, at the sound of the second bell, and all subsequent bells, you should move to the next table* and begin your networking with the new group of people. * All delegates with blue cards move clockwise, and all delegates with green cards move anticlockwise. Directions will also be indicated on the tables. 5. The networking session will finish when you are back with your original group. TIP: Use your envelope to collect business cards of your new acquaintances!

Wednesday

4 March

1.45 PM

 Masami Todokoro, Bioprocess Equipment Manager, JNC Corporation  Shigeyuki Aoyama, Cellufine Sales Manager, JNC Corporation

Chromatography Media: New Chromatography Systems for Downstream Processing

Thursday

5 March

1.30 PM

LUNCHTIME TECHNICAL WORKSHOP SCHEDULE

Culture and Immunology, Himedia Laboratories Pvt. Ltd., India

 Vishal G. Warke, Director R&D, Cell

High quality with low cost: Strategies for staying ahead in the Indian Biosimilars market

Lunchtime Technical Workshop Venue

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Media Partners

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Outside Conference Pune Hours

is the second city of the state of Maharashtra after Mumbai and the eighth largest city in India. It has an ancient tradition of grandeur and of warm hospitality and a majestic history of over 1200 years to tell. In the 18th century, Pune became the centre of Indian politics and then served as the "monsoon capital" of the Bombay Presidency until the independence of India. It is also the centre of traditional Marathi culture, in which education, arts and crafts, and theatre are given pride of place. The narrow winding roads of the old Pune offer an interesting contrast to the open, spacious new city. The area is suffused with colorful sites, from ancient forts to expansive gardens, and the city is known for its high educational facilities and relative prosperity, which have allowed it to become a cosmopolitan city as well as an important commercial centre. However, Pune retains the old-world charm and its many quaint characteristics, including the omnipresent cyclists and rickshaws. Queen of the Deccan, Oxford of the East, Pune is a city with a future that promises to be as interesting as its history.

AGA KHAN PALACE Aga Khan Palace is a majestic building and is considered to be one of the greatest marvels of India. It was built in 1892 by Imam Sultan Muhammed Shah Aga Khan III as an act of charity to help the poor drastically hit by famine. Following the launch of Quit India movement in 1942, Gandhi, his wife Kasturba and his secretary Mahadevbhai Desai were interned at the palace from August 1942 to May 1944, where Mahadevbhai and Kasturba passed away. The palace has developed into a national and international place of pilgrimage with over 100.000 visitors every year paying homage to their samadhis and ashes of Mahatma Gandhi.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

OSHO INTERNATIONAL MEDITATION RESORT The Osho International Meditation is the ashram of Osho, also known as Acharya Rajneesh, a mystic, guru, and spiritual teacher who garnered an international following. The Osho resort is the world's largest meditation center and it is spread over 31 acres of flush green surroundings. It is a spiritual oasis made of marble pathways, elegant black buildings, and abundant foliage. Over 100 different meditation techniques are offered to visitors coming from over 60 countries to experience the spiritual journey.

RAJA DINKAR KELKAR MUSEUM The museum is housed in a Rajasthani styled building situated close to the hustle and bustle of the busy Bajirao Road of Pune. It holds the collection of Dr Dinkar G. Kelkar (1896–1990), dedicated to the memory of his only son, Raja, and includes some of the most fascinating Indian art crafts. The exhibition consists of more than 2500 Indian decorative items from everyday life and other art objects, mostly from the 18th and 19th centuries.

SHREEMANT DAGDUSHETH HALWAI SARVAJANIK GANPATI Srimanth Dagaduseth Ganpati temple Pune is one of the most important and visited Ganesh temple in Maharashtra. It was built by Dagdusheth Halwai, a successful sweetmeat seller and a rich businessman in Pune, in 1893, to shun away his grief after the death of his son. The Ganesh idol is a sheer beauty: the 7.5 feet tall and 4 feet wide idol is adorned with nearly 8 kilos of gold and is enriched by the devotees’ offerings.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

DARSHAN MUSEUM Darshan museum is dedicated to the noted Sindhi Saint and scholar, Sadhu T. L. Vaswani (1879-1966), an Indian educationist who started the Mira movement of education and set up the Sadhu Vaswani Mission (The organization is well known for its philanthropic work in the fields of education, healthcare, rural development, spiritual upliftment and feeding of the poor through its community kitchens). It offers an insight into Sadhu Vaswani’s life and teachings. Darshan is not a conventional museum: the exhibition is done through 3D Holographics, Life-Like Statues, Realistic Sets, Hi-Def Audio, HD Video, Theatrical Lighting and much more. The visitor literally 'walks' into a scene which is played before his/her eyes.

PARVATI HILL The hillock of Parvati Hill rises up to 2,100 feet (640 m) above sea level. Atop the hillock is the Parvati Temples, which are one of the most scenic locations in Pune. The temple is the oldest heritage structure in Pune and was built in the Peshwa Dynasty rule (17th to 19th century). It is also used as an observation spot for visitors of the panorama of Pune since it is the second highest point in Pune premises after Vetal Hill. The hill has 103 steps, which is the way to the top of the hill where the temple is situated. The main temple, Devdeveshwara, is made of Blackstone. It was completed under Nanasaheb Peshwa, in 1749. Other temples are dedicated toVitthal and Rukmini, Vishnu, and Kartikeya.

Day 1 4 March 2015

CONFERENCE AGENDA Wednesday, March 04, 2015 Registration Commences

9:05 a.m.

IMAPAC's Welcome Remarks  Chamindika Konara, Conference Manager, IMAPAC, Singapore

9:10 a.m.

Chairman’s Opening Remarks  Reinhard Glueck, Chief Scientific Officer, Zydus Cadila, India

9:15 a.m.

Exhibits Open

8:00 a.m.

Keynote Leadership Panel: Economics of Developing Vaccine Industry: Expert Insights from Industry Leaders from Emerging Markets  Reinhard Glueck, Chief Scientific Officer, Zydus Cadila, India (Moderator)  Suresh Jadhav, Executive Director, Serum Institute of India, India (Panelist)  Subhra Ranjan Chakrabarti, Associate Vice President, Shantha Biotechnics, India (Panelist)  Krishna Ella, Chairman, Founder, Bharat Biotech, India (Panelist)

10:00 a.m.

Addressing the Gap in Adult and Child Vaccine Markets for Developing Countries: Vaccine Accessibility  Suresh Jadhav, Executive Director, Serum Institute of India, India

10:30 a.m.

Morning Refreshments and Speed Networking

11:00 a.m.

Managing Cost Considerations & Access to Technology for Cost-Effective Vaccine Manufacture  S. D Ravetkar, Executive Director, Serum Institute of India, India

11:30 a.m.

Clean Manufacturing for Vaccine Production and Productivity Optimization  Upendra Jani, Vice President, Quality Assurance, Hester Biosciences, India

12:00 p.m.

Novel Cell Culture-Based Virus Production Using Serum-Free Cell Culture Medium  Sanjoy Mukherjee, General Manager, Global Field Application, Hyclone - LSCell Culture, GE Healthcare, India

12:30 p.m.

Investigating Out Of Trend (OOT) Test Results  Pradeep Nagalkar, Head, Quality Control, Haffkine Biopharma, India

1:00 p.m.

Lunch Networking Session + Lunch Technical Workshop by M R Sanghavi: Chromatography Media: New Chromatography Systems for Downstream Processing  Masami Todokoro, Bioprocess Equipment Manager, JNC Corporation , Japan  Shigeyuki Aoyama, Cellufine Sales Manager, JNC Corporation , Japan

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

2:20 p.m.

Managing cGMP Multi-Product Facility for Vaccine Manufacture  Anil Sood, Vice President and Site Head, Panacea Biotec, India

2:50 p.m.

Viral Vaccine Platforms  Chidananda Chandrashekaraiah, Bioprocess Specialist, Pall Corporation , India

3:10 p.m.

HLL’s Experience: Do’s and Don’ts in New Plant Commissioning  Raman Ramachandran, CEO, HLL Biotech, India

3:40 p.m.

Afternoon Refreshments

4:00 p.m.

Preparing Developing Countries for the Dengue Epidemic

4:30 p.m.

Manufacturing Alternative Quadrivalent Vaccines for Developing Countries  Kutub Mahmood, Scientific Director, PATH, USA

5:00 p.m.

Rapid Development & Manufacturing of an Ebola Vaccine Candidate  Milind Patole, Scientist, National Centre of Cell Sciences, India

5:30 p.m.

Chairman’s Closing Remarks  Reinhard Glueck, Chief Scientific Officer, Zydus Cadila, India

5:35 p.m.

End of Conference Day 1 I Welcome Cocktail

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Chairman’s Opening Remarks Reinhard Glueck, Chief Scientific Officer, Zydus Cadila, India 2001-2005: Board of Directors for Pevion GmbH, Berne from 2001: President of Etna Biotech Srl, Catania from 2002: President Swiss Biotech Association from 2002: Board of Directors for Nexatio AG, Basel from 2003: Adjunct Professor University of Catania for Biotechnology and Immunology of the Institute of Pharmacology and Hygiene from 2003: Instructor for Prevention and Vaccination of University of Genova, Department Science of Health from 2003: Scientific Board for INB, USA from 2004: Editorial Board Member for the Journal of Human Vaccines from 2005: Scientific Board of AMVAC, Zug from 2006: Executive Vice President R&D, Vaccine Discovery, Crucell from 2006: Member of Scientific Board, Swiss Universities of Applied Sciences from 2006; Chairman, European Malaria Vaccine Development Association (EMVDA) from 2007: Board of International Society for Influenza and other Respiratory Virus Diseases (ISIRV) from 2008: Scientific Advisor of Redbiotech, Zurich from 2009: Chief Scientific Officer – Vaccines, Cadila Healthcare (Zydus)

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Keynote Leadership Panel: Economics of Developing Vaccine Industry: Expert Insights from Industry Leaders from Emerging Markets Reinhard Glueck, Chief Scientific Officer, Zydus Cadila, India (Moderator) 2001-2005: Board of Directors for Pevion GmbH, Berne from 2001: President of Etna Biotech Srl, Catania from 2002: President Swiss Biotech Association from 2002: Board of Directors for Nexatio AG, Basel from 2003: Adjunct Professor University of Catania for Biotechnology and Immunology of the Institute of Pharmacology and Hygiene from 2003: Instructor for Prevention and Vaccination of University of Genova, Department Science of Health from 2003: Scientific Board for INB, USA from 2004: Editorial Board Member for the Journal of Human Vaccines from 2005: Scientific Board of AMVAC, Zug from 2006: Executive Vice President R&D, Vaccine Discovery, Crucell from 2006: Member of Scientific Board, Swiss Universities of Applied Sciences from 2006; Chairman, European Malaria Vaccine Development Association (EMVDA) from 2007: Board of International Society for Influenza and other Respiratory Virus Diseases (ISIRV) from 2008: Scientific Advisor of Redbiotech, Zurich from 2009: Chief Scientific Officer – Vaccines, Cadila Healthcare (Zydus)

Suresh Jadhav, Executive Director, Serum Institute of India, India (Panelist) Dr.Suresh Jadhav, M.Pharm., Ph.D. is the Executive Director of Serum Institute of India Ltd., one of the largest vaccine manufacturers from the developing countries, supplying vaccines to more than 140 countries through U.N. Agencies at affordable prices. Dr. Jadhav also led the project of development and introduction of Meningococcal A Conjugate Vaccine in Sub-Saharan African belt, the development of Seasonal & Pandemic Influenza Vaccines and also played major role in acquisition of Bilthoven Biologicals, a Netherlands based Govt. Vaccine manufacturing company. Dr.Jadhav is associated with Developing

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Countries Vaccine Manufacturers’ Network (DCVMN) since its inception in 2000 and was the President of DCVMN from 2003 till 2008. He is currently member/alternate member on various boards i.e. GAVI, European Vaccine Initiative, FastVac, and Health Innovation in Practice Board besides GAVI PPC member. He is closely associated with various advisory committees e.g. Task Force of Sabin Vaccine Institute, WHO IVR-IVAC and Decades of Vaccines (DoV) etc. Dr.Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc. He is Chairman of Expert Committee on Vaccines and other Biologicals and also a member on the Scientific Body of Indian Pharmacopoeia Commission. He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, NVI etc. and has published more than 60 technical papers in national & international journals, with extensive travel throughout the globe. He has to his credit two patents in his name. Ranked at 7th position amongst Worlds 50 most influential people in Vaccines surveyed by Vaccinenation of Terrapinn.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Subhra Ranjan Chakrabarti, Associate Vice President, Shantha Biotechnics, India (Panelist)

Krishna Ella, Chairman, Founder, Bharat Biotech, India (Panelist) Dr. Krishna Ella is the Chairman & Managing Director of Bharat Biotech International Limited. After early education in Agricultural Sciences, Dr. Ella studied at the University of Hawaii and the University of Wisconsin-Madison. Following a brief stint as a research faculty at the Medical University of South Carolina-Charleston, he returned to India and set up Bharat Biotech International Limited, a multidimensional biotechnology company specializing in R&D, manufacturing and marketing of vaccines and biotherapeutics for human use. Today, Bharat Biotech is one of the leading innovative R&D Companies, with 45 global patents, of which 5 are for new molecules. Bharat Biotech has been funded (>300 crores) by various agencies like DBT, CSIR, DST and Bill & Melinda Gates Foundation. Dr. Ella is an accomplished scientist with expertise in gene knock-out and expression systems. As an entrepreneur with over two decades of experience in product development and manufacturing, he has recently ventured into other areas like veterinary vaccines (Biovet), food processing (Innova Agri Bio), functional foods (Century Biologicals), contract research services (RCC Labs) and developing biotechnology infrastructure (Konark Bio Park). He has received several awards for his academic recognitions like the Rotary Fellowship, and the National Research Service Award of the National Institute of Health, U.S.A. Further, he has been honoured for his entrepreneurial skills with awards such as, J.R.D. TATA – Best Entrepreneur of the Year and Marico Innovation award received from the Prime Minister of India, among several others. Dr. Ella is also involved in shaping India’s science education and policy as well as International collaboration by being a Member, Advisor or Chairman of numerous committees. The prominent ones among these include Five Year Plan

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

for Biotechnology, Human Resource and Innovation, National Biotech Policy, High Technology Cooperation Groups, National Task Force in Industrial Biotechnology, National Council of IPR. He has recently been nominated as a Member of the Scientific Advisory Committee to the Prime Minister of India.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Addressing the Gap in Adult and Child Vaccine Markets for Developing Countries: Vaccine Accessibility Suresh Jadhav, Executive Director, Serum Institute of India, India Dr.Suresh Jadhav, M.Pharm., Ph.D. is the Executive Director of Serum Institute of India Ltd., one of the largest vaccine manufacturers from the developing countries, supplying vaccines to more than 140 countries through U.N. Agencies at affordable prices. Dr. Jadhav also led the project of development and introduction of Meningococcal A Conjugate Vaccine in Sub-Saharan African belt, the development of Seasonal & Pandemic Influenza Vaccines and also played major role in acquisition of Bilthoven Biologicals, a Netherlands based Govt. Vaccine manufacturing company. Dr.Jadhav is associated with Developing Countries Vaccine Manufacturers’ Network (DCVMN) since its inception in 2000 and was the President of DCVMN from 2003 till 2008. He is currently member/alternate member on various boards i.e. GAVI, European Vaccine Initiative, FastVac, and Health Innovation in Practice Board besides GAVI PPC member. He is closely associated with various advisory committees e.g. Task Force of Sabin Vaccine Institute, WHO IVR-IVAC and Decades of Vaccines (DoV) etc. Dr.Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc. He is Chairman of Expert Committee on Vaccines and other Biologicals and also a member on the Scientific Body of Indian Pharmacopoeia Commission. He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, NVI etc. and has published more than 60 technical papers in national & international journals, with extensive travel throughout the globe. He has to his credit two patents in his name. Ranked at 7th position amongst Worlds 50 most influential people in Vaccines surveyed by Vaccinenation of Terrapinn.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Managing Cost Considerations & Access to Technology for Cost-Effective Vaccine Manufacture S. D Ravetkar, Executive Director, Serum Institute of India, India Dr. S.D. Ravetkar is Executive Director with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national and international organizations and journals. He has more than 41 years techno-commercial experience in biotech industry in various areas like QC, production, projects & research. At present his major responsibility is manufacturing of Bacterial combination vaccines mainly Penta vaccine. He has extensively worked on microbial and bioengineering aspects of vaccinology and also has got expertise on technology transfer. He has widely travelled worldwide.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Clean Manufacturing for Vaccine Production and Productivity Optimization Upendra Jani, Vice President, Quality Assurance, Hester Biosciences, India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Novel Cell Culture-Based Virus Production Using Serum-Free Cell Culture Medium Sanjoy Mukherjee, General Manager, Global Field Application, Hyclone - LS-Cell Culture, GE Healthcare, India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Investigating Out Of Trend (OOT) Test Results Pradeep Nagalkar, Head, Quality Control, Haffkine Biopharma, India • Dr. Pradeep Nagalkar is a Microbiologist. •He has completed his post graduation from Seth G. S. Medical College & K.E.M. Hospital, Parel, Mumbai. • He has Completed his Ph.D. in Microbiology from University Department of Chemical Technology (UDCT) now UICT, Mumbai. • He was Awarded R.D. Birla Smarak Kosh Scholarship, Bombay Hospital, for carrying research work for his Post graduation and for Doctorate. • He has worked on studies in Endotoxin and animal tests in various fields like biopharmaceuticals, plasma fractionation, food technology etc. He also studied on comparisons of animal tests and Endotoxin test. • He had studied and standardized the test for bacterial endotoxin for various applications before it was introduced in Indian Pharmacopoeia. • He has Extensive knowledge of Protein purification and Biological testing. • At Present he is working as a Head, Quality Control at Haffkine BioPharmaceutical Corp. Ltd. since last 13 years. • He is responsible for all quality control (Chemical and Biological) related to various Vaccines and Antiseras, Pharmaceutical products like tablets, oral liquids. • He has researched, analyzed and interpreted primary and secondary information from literature surveys. Designed and implanted structured plan for research. Extensive knowledge of Protein purification and Biologicals testing, FDA rules and regulations. Produced qualitative thesis study. •He has completed experiments in Protein extraction, large scale and laboratory scale Chromatography techniques, Protein and Biologicals quality control. •Extensive experience of working in direct skills contact with research scholars, students and workers, • He is a member of IPR sub-committee for Indian Drug Manufactures Association (IDMA). He is also deputed for various workshops and attended many conferences, symposiums and delivered many lecturers in national and international conferences.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Lunch Technical Workshop by M R Sanghavi: Chromatography Media: New Chromatography Systems for Downstream Processing 1. Masami Todokoro PhD; Bioprocess equipment manager JNC Corporation, Japan 2. Shigeyuki Aoyama; Cellufine sales manager, JNC Corporation, Japan



JNC Corporation would like to present two topics below in the workshop. 1) Chromatography media “Cellufine” for vaccine manufacturing 2) Launched our new business; Column and equipments from pilot scale to commercialization for bio-pharmaceuticals production At first, we introduce chromatography media Cellufine. Cellufine is porous and spherical particle from cellulose which has chemical stability, mechanical strength and good bio-compatibility. All Cellufine products are manufactured in Japan and guaranteed by ISO. One of Cellufine products, Cellufine Sulfate is used for virus purification because of its unique ligand designed to mimetic heparin. In this workshop, we show some applications of virus purification with the media. Second, we introduce our new business which contributes to accelerate commercial production of bio-pharmaceuticals. We offer new products launching, column, packing equipment and control system with competitive price. Columns are prepared in five different diameters (100, 140, 200. 300 and 450 mm) as usage and all equipments are designed easy to operate.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Managing cGMP Multi-Product Facility for Vaccine Manufacture Anil Sood, Vice President and Site Head, Panacea Biotec, India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Viral Vaccine Platforms Chidananda Chandrashekaraiah, Bioprocess Specialist, Pall Corporation , India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

HLL’s Experience: Do’s and Don’ts in New Plant Commissioning Raman Ramachandran, CEO, HLL Biotech, India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Preparing Developing Countries for the Dengue Epidemic

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Manufacturing Alternative Quadrivalent Vaccines for Developing Countries Kutub Mahmood, Scientific Director, PATH, USA Dr. Kutub Mahmood is the Scientific Director of the Polio Vaccine Development Project, at the nonprofit organization PATH, based in Seattle, Washington. The polio vaccine project is part of PATH’s broader effort to develop low-cost vaccine supplies for the global markets. Dr. Kutub Mahmood focuses primarily on conducting technical assessment for vaccine manufacturers and providing support to help them achieve WHO pre-qualification for their vaccine products. He also works to identify potential partnerships with multinational pharmaceutical companies, biotech firms, and public/private enterprises. He joined PATH in March 2012 after 20 years leading vaccine discovery and product development efforts in private industry, with stints at Medimmune, Novavax, and other start-up vaccine companies including Vivaldi Biosciences. Dr. Mahmood made numerous contributions to the successful development of the FluMist®, a live attenuated influenza vaccine.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Rapid Development & Manufacturing of an Ebola Vaccine Candidate Milind Patole, Scientist, National Centre of Cell Sciences, India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Chairman’s Closing Remarks Reinhard Glueck, Chief Scientific Officer, Zydus Cadila, India 2001-2005: Board of Directors for Pevion GmbH, Berne from 2001: President of Etna Biotech Srl, Catania from 2002: President Swiss Biotech Association from 2002: Board of Directors for Nexatio AG, Basel from 2003: Adjunct Professor University of Catania for Biotechnology and Immunology of the Institute of Pharmacology and Hygiene from 2003: Instructor for Prevention and Vaccination of University of Genova, Department Science of Health from 2003: Scientific Board for INB, USA from 2004: Editorial Board Member for the Journal of Human Vaccines from 2005: Scientific Board of AMVAC, Zug from 2006: Executive Vice President R&D, Vaccine Discovery, Crucell from 2006: Member of Scientific Board, Swiss Universities of Applied Sciences from 2006; Chairman, European Malaria Vaccine Development Association (EMVDA) from 2007: Board of International Society for Influenza and other Respiratory Virus Diseases (ISIRV) from 2008: Scientific Advisor of Redbiotech, Zurich from 2009: Chief Scientific Officer – Vaccines, Cadila Healthcare (Zydus)

Day 2 5 March 2015

CONFERENCE AGENDA Thursday, March 05, 2015 Registration Commences

9:00 a.m.

IMAPAC's Welcome Back Remarks  Chamindika Konara, Conference Manager, IMAPAC, Singapore

9:05a.m.

Chairman's Opening Remarks  Kutub Mahmood, Scientific Director, PATH, USA

9:10 a.m.

Vaccines: Journey from Medieval Era to 21st Century with Special Reference to Indian Vaccine Industry and A Look Toward The Future  Sunil Gupta, Director, CRI, Central Drug Standard Control Organization, Kasauli, Government of India, India

9:40 a.m.

10:10 a.m.

Addressing the Issue of Drug Pricing for Both Patients and Vaccine Manufacturers in Developing Countries  Ajay Gambhir, Head Neonatology & Pediatrics, Saroj Hospital & Heart Institute , India

10:40 a.m.

Exhibits Open

8:00 a.m.

Morning Refreshment

11:10 a.m.

Improving Access to Vaccination  Sanjay Gandhi, Area Medical Leader (South Asia), GSK Vaccines, India

11:40 a.m.

Case Study: MenAfrivac Success Story - Taking Products to the Masses  Hitesh Malviya, Additional Director, Polysaccharide Conjugate Vaccines, Serum Institute of India, India

12:10 p.m.

Influenza Seasonality & Vaccination Timing in the Tropics & Sub-Tropics

12:40 p.m.

Lunch Networking Session + Lunch Technical Workshop by HiMedia: High quality with low cost: Strategies for staying ahead in the Indian Biosimilars market  Vishal G. Warke, Director R&D, Cell Culture and Immunology, Himedia Laboratories Pvt. Ltd., India

2:00 p.m.

Case Study: Innovations in Prophylactic Vaccination: Challenges and Avenues in

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Developing Cost Effective Conjugate Vaccines  Manoj Kumar, Associate Director, MSD Welcome Trust Hilleman Labs, India Cost-Effective Innovations in Malaria Vaccine Space

3:00 p.m.

Case Study: Innovations in the HIV Vaccine Space: Technological Advances for Accelerating Development of Vaccines  Jayanta Bhattacharya, Principal Scientist II, IAVI, India

3:30 p.m.

Afternoon Refreshments

3:50 p.m.

Abivax: A Novel Player in Anti-Virals and Specialty Vaccines  Pierre Courteille, Chief Commercial Officer & Vice President Business Development, ABIVAX, France

4:20 p.m.

4:50 p.m.

Exhibits Open

2:30 p.m.

Adjuvant Past, Present and Future  Gaurav Gupta, Head, Virology, Biotechnology Research Centre, Zydus Cadila, India Novel Vaccine Candidate Using an Immunogen Optimization System  Nirajan Kumar

5:20 p.m.

Chairman's Closing Remarks  Kutub Mahmood, Scientific Director, PATH, USA

5:30 p.m.

End of Conference Day 2

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Chairman’s Opening Remarks Kutub Mahmood, Scientific Director, PATH, USA Dr. Kutub Mahmood is the Scientific Director of the Polio Vaccine Development Project, at the nonprofit organization PATH, based in Seattle, Washington. The polio vaccine project is part of PATH’s broader effort to develop low-cost vaccine supplies for the global markets. Dr. Kutub Mahmood focuses primarily on conducting technical assessment for vaccine manufacturers and providing support to help them achieve WHO pre-qualification for their vaccine products. He also works to identify potential partnerships with multinational pharmaceutical companies, biotech firms, and public/private enterprises. He joined PATH in March 2012 after 20 years leading vaccine discovery and product development efforts in private industry, with stints at Medimmune, Novavax, and other start-up vaccine companies including Vivaldi Biosciences. Dr. Mahmood made numerous contributions to the successful development of the FluMist®, a live attenuated influenza vaccine.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Vaccines: Journey from Medieval Era to 21st Century with Special Reference to Indian Vaccine Industry and A Look Toward The Future Sunil Gupta, Director, CRI, Central Drug Standard Control Organization, Kasauli, Government of India, India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Case Study: From Concept to Market: Research and Effective Clinical Studies in Indian Vaccine Development Including Effective Post-Licensure Surveillance: Japanese Encephalitis Arani Chatterjee, Senior Vice President, Clinical Research, , Biological E, India Arani Chatterjee is a graduate of CMC, Vellore and postgraduate from NIMHANS, Bangalore and IIM, Indore. He has an experience of over 17 years, is a visiting faculty at many institutes, member of several expert committees, has participated in numerous national/international regulatory meetings and has 18 publications in peer-reviewed journals.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Addressing the Issue of Drug Pricing for Both Patients and Vaccine Manufacturers in Developing Countries Ajay Gambhir, Head Neonatology & Pediatrics, Saroj Hospital & Heart Institute , India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Improving Access to Vaccination Sanjay Gandhi, Area Medical Leader (South Asia), GSK Vaccines, India Sanjay is Public Health Specialist. He brings rich experience in leading and managing large health projects in various settings with multiple stakeholders and effectively managed expected outcomes in diverse environments. Sanjay Gandhi is currently designated as Area Medical Leader (AML) for South Asia at GlaxoSmithKlines Vaccines and is responsible for Clinical Research & Medical Affairs. He is physician with specialization in Public health from Nagpur University. He started his professional career as Medical faculty at Grant Medical College, Mumbai under Govt. of Maharashtra. After 7 years of teaching he got associated with WHO Polio Surveillance project and PATH, an international NGO, for 14 years working on various vaccine preventable diseases in heterogeneous environment of 6 different states of India. He was responsible for establishing customized surveillance system; strengthening Immunization program; new vaccine introduction projects and leading need based short training courses on clinical research. He is an alumnus of ADVAC (Advance course in Vaccinology) organized by Fondation Mérieux & Université de Genève; visiting faculty to couple of Institutes in India and have couple of publications in National and International Journals to his credit. He believes in philosophy of ‘Prevention is better than cure’ and aiming for universal access to all vaccination by all eligibles. He can be reached at sanjay.t.gandhi@gsk.com or drsanjaygandhi@gmail.com

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Case Study: MenAfrivac Success Story - Taking Products to the Masses Hitesh Malviya, Additional Director, Polysaccharide Conjugate Vaccines, Serum Institute of India, India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Influenza Seasonality & Vaccination Timing in the Tropics & Sub-Tropics

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Lunch Technical Workshop by HiMedia: High quality with low cost: Strategies for staying ahead in the Indian Biosimilars market Vishal G. Warke, Director R&D, Cell Culture and Immunology, Himedia Laboratories Pvt. Ltd., India

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Case Study: Innovations in Prophylactic Vaccination: Challenges and Avenues in Developing Cost Effective Conjugate Vaccines Manoj Kumar, Associate Director, MSD Welcome Trust Hilleman Labs, India Dr. Manoj Kumar is an Immunobiologist with a Ph.D. in Bacteriology, presently working as Associate Director, R&D at MSD Wellcome Trust Hilleman Labs heading the conjugate vaccine research portfolios focusing on development of novel technologies. He worked in R&D Department of Serum Institute of India during 2004-2013, on several vaccine and biosimilar product development projects. He has 9 patent applications, 10 publications, 1 book chapter, 4 popular articles, 7 gene sequences, 12 national and international awards in his name. He is a contributing scientist on revision of WHO Technical Report Series (TRS927 Annex 2) for manufacture and evaluation of pneumococcal conjugate vaccines. His focus areas include: New vaccine development; Cost effective vaccine technologies; Developing faster analytical methods and Technology transfers.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Cost-Effective Innovations in Malaria Vaccine Space

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Case Study: Innovations in the HIV Vaccine Space: Technological Advances for Accelerating Development of Vaccines Jayanta Bhattacharya, Principal Scientist II, IAVI, India Dr. Jayanta Bhattacharya is a Principal Scientist II (Research and Development) at the International AIDS Vaccine Initiative, India. As a Principal Investigator at the HIV Vaccine Translational Research Laboratory (HVTR), Gurgaon, a collaborative endeavor of the Translational Health Science & Technology Institute and International AIDS Vaccine Initiative, he is working on discovery of novel broad and potent antibodies from Indian patients using reverse vaccinology. A Ph.D from the University of Calcutta, India, before joining IAVI, Dr. Bhattacharya worked as a Deputy Director (Scientist E) in the Division of Molecular Virology at the National AIDS Research Institute (NARI), Indian Council of Medical Research, Pune, prior to which, he was an Instructor in the Department of Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA. He is a recipient of a number of awards and is in the Editorial Board of some prestigious journals and boasts of several publications in peer reviewed journals.  See overleaf for Topic Summary

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/



o Development of efficacious vaccines (both protective and prophylactic) to major global diseases such as AIDS, malaria, influenza etc. will considerably fill the gap that remains towards comprehensively lowering the incidence thereby benefitting public health and society to a significant extent. o Recent technological innovations highlighting advances in HIV vaccine discovery has provided new avenues in decrypting mechanism of immune evasion despite challenges in combating pathogen diversity and complex host immune repertoire. o Such advanced technologies will help accelerate design and early development of vaccines.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Abivax: A Novel Player in Anti-Virals and Specialty Vaccines Pierre Courteille, Chief Commercial Officer & Vice President Business Development, ABIVAX, France Pierre has more than 20 years experience? in marketing and sales within the pharmaceutical industry in France and in Japan, where he has worked for 13 years. He holds a pharmacy degree and MBA from Chicago Booth University (USA). At Sanofi-Pasteur Japan, and its joint-venture with Daiichi, Pierre Courteille was in charge of the pre-launch activities of HIB/meningitis and IPV/polio vaccines? as Marketing Manager. At the start of 2005, he became President of Guerbet Japan and VP for Guerbet Asia. He successfully managed the roll-out of its Japanese subsidiary and led the development of other branches in Asia. From 2009, Pierre served as VP Sales for Asia, Latin America and EMEA and met the ambitious objective of optimizing commercial performance across these 3 regions. Prior to joining ABIVAX, Pierre was Senior VP sales and marketing for Guerbet and CEO of MEDEX (medical devices company owned by Guerbet) from 2012.



BUILDING A GLOBAL LEADER IN HUMAN VACCINES AND ANTI-VIRAL DRUGS « Novel medicines to deliver long lasting control of viral load » Our goal is to be a global leader in the discovery, development and commercialisation of human vaccines and anti-viral drugs with a long-lasting therapeutic effect to treat some of the world’s most threatening viral disease: Chronic Hepatitis B, HIV, Dengue, Ebola, Chikungunya

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Adjuvant Past, Present and Future Gaurav Gupta, Head, Virology, Biotechnology Research Centre, Zydus Cadila, India He is working as Deputy General Manager with role of Head Virology & Biotechnology in Zydus Cadila, Ahmedabad, India. He has overall 11 years of industrial and 2 years of academic experience in research, development & commercialization of classical viral and genetically engineered vaccines. He has worked for Biomed and Panacea Biotech until March 2009. He is leading vaccines development & operations based at Ahmedabad, India and Catania, Italy for live, killed and genetic engineered vaccines. Currently 9 of his vaccines are in advance stages of Phase II/III trials. He has about 19 publications & 2 patents.



The vaccine antigens produced by different technologies includes live attenuated, killed and recombinant DNA derived. In case of live attenuated vaccines like Measles, Mumps, Rubella and Varicella etc, the need for stimulating immune response to achieve desired immune response is fulfilled by antigens alone in stabilizing excipients. Such vaccines are globally proven on safety and efficacy parameters worldwide by now since many decades. On the other hand killed & new generation recombinant DNA derived/ synthetic vaccines mostly require either humoral or cellular adjuvants to augment the effect of vaccine by stimulating the immune response, more vigorously and thus providing increased immunity to a particular disease .e.g. DPTHib-HepB, Influenza, HPV, Dengue, Malaria & Leishmania etc.

The most classical adjuvants used so far are Alum based and oil based for human & veterinary use. They have been proven for giving sustained and vigorous immune responses viz a viz acceptable safety profile in human and animals. This revie depending upon disease conditions with their examples.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Novel Vaccine Candidate Using an Immunogen Optimization System Nirajan Kumar

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

Chairman’s Closing Remarks Kutub Mahmood, Scientific Director, PATH, USA Dr. Kutub Mahmood is the Scientific Director of the Polio Vaccine Development Project, at the nonprofit organization PATH, based in Seattle, Washington. The polio vaccine project is part of PATH’s broader effort to develop low-cost vaccine supplies for the global markets. Dr. Kutub Mahmood focuses primarily on conducting technical assessment for vaccine manufacturers and providing support to help them achieve WHO pre-qualification for their vaccine products. He also works to identify potential partnerships with multinational pharmaceutical companies, biotech firms, and public/private enterprises. He joined PATH in March 2012 after 20 years leading vaccine discovery and product development efforts in private industry, with stints at Medimmune, Novavax, and other start-up vaccine companies including Vivaldi Biosciences. Dr. Mahmood made numerous contributions to the successful development of the FluMist®, a live attenuated influenza vaccine.

CONFERENCE EVALUATION CHAIRMAN / SPEAKER ASSESSMENT E = Excellent

VG = Very Good

G = Good

S = Satisfactory

Conference Day 1 Speaker

Presentation skills

P = Poor

4 March 2015 / Wednesday

Content of session

Speaker

Presentation skills

Content of session

R. Glueck Chairperson

E VG G

VG G

Upendra Jani

E VG G

VG G

Reinhard Glueck -Panel

E VG G

VG G

Sanjoy Mukherjee

E VG G

VG G

Suresh Jadhav -Panel

E VG G

VG G

Pradeep Nagalkar

E VG G

VG G

Subhra R.C -Panel

E VG G

VG G

Anil Sood

E VG G

VG G

E VG G

VG G

Chidananda C.

E VG G

VG G

Suresh Jadhav

E VG G

VG G

Raman R.

E VG G

VG G

S.D Ravetkar

E VG G

VG G

Kutub Mahmood

E VG G

VG G

Milind Patole

E VG G

VG G

Krishna Ella Panel

Conference Day 2

5 March 2015 / Thursday

Content of session

Presentation skills

K. Mahmood -Chairperson

E VG G

VG G

Manoj Kumar

E VG G

VG G

Sunil Gupta

E VG G

VG G

Jayanta Bhattacharya

E VG G

VG G

Arani Chatterjee

E VG G

VG G

Pierre Courteille

E VG G

VG G

Ajay Gambhir

E VG G

VG G

Gaurav Gupta

E VG G

VG G

Sanjay Gandhi

E VG G

VG G

Nirajan Kumar

E VG G

VG G

Hitesh Malviya

E VG G

VG G

Name

Job Title

Speaker

Presentation skills

Speaker

Company ď&#x192; Please turn overleaf

Comments on conference programme:

Which speaker(s) / topic(s) did you particularly come to hear?

What objective do you like to achieve by attending the conference?

What can IMAPAC do in the future to improve your conference experience?

CONFERENCE 1.

Did you benefit from attending this conference? Is your objective met? If no, why?

YES / NO

Was the conference up to your expectations?

YES / NO

Comments on the Conference as a whole (may we use your quote as a testimonial for our future events?)

How would you rate this conference overall?

E VG G

How would you rate IMAPACâ&#x20AC;&#x2122;s customer service? a) Pre-Conference

E VG G

b) Conference Day

E VG G

CONFERENCE VENUE / FACILITIES

Conference Room

E VG G

Catering

E VG G

Audio visual equipment

E VG G

Service (by venue)

E VG G

Cocktail

E VG G

THANK YOU! Thank you for taking the time to complete this questionnaire. We value your opinions and comments, and will use this information to assist us in improving our service.

THANKS TO OUR

Sponsors IMAPAC would like to thank the following sponsors for their support and

contribution

making

SUMMIT INDIA 2015

VACCINE

WORLD

a success. Hope to see you again in

2016. P LA TI N U M SP ON SOR GE HEALTHCARE LIFE SCIENCES provides tools and technologies, solutions and expertise which enable the biopharmaceutical industry to develop and manufacture biotherapeutic medicines and vaccines cost-effectively. Our products and platform solutions are designed to meet the key challenges posed at every stage in the biomanufacturing process, delivering the desired product at the required purity and safety: all with fast development and integrated solutions in mind. Across the bioprocessing spectrum, our focus is on supporting you from idea to result.

GOLD SP ON SOR BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit our website at www.bd.com.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

LU N CH TI M E WOR K SH OP SP ON SOR

Through the wide range of our products and services, M R SANGHAVI plans to assist Pharmaceuticals, Biotech & Fine Chemical Industries & Indian Universities and Institutes. To the suppliers, on the other hand, we provide complete marketing, market development selling and distribution services in professional and effective manner. JNC CORPORATION is a Japanese leading chemical company founded in 1906. Our aim is to contribute to society’s progress through superior technology. We have 23 business locations all over the world and we produce innovative products in the field of advanced information materials, energy materials, chemicals, and processed goods. We continue to engage in R&D and production technology to expand our business. For more information, please visit our homepage (http://www.jnc-corp.co.jp/english/). JNC Corporate Profile Head Office 2-2-1 Otemach, Chiyoda-ku, Tokyo, Japan Founded 1906 Paid-in 31.15 billion JPY capital Holding Chisso Corporation Company Main Liquid crystals, Fertilizer, Bicomponent fiber, Functional products filter, Silicon products, Solvent, Chromatography media (Cellufine) Homepage

http://www.jnc-corp.co.jp/english/

A SSOCI A TE SP ON SOR PALL LIFE SCIENCES is a leading provider of separation systems and singleuse filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall’s Scientific and Laboratory Services (SLS), Technical Services and Validation Laboratories have been a cornerstone of customer support for over 30 years. The company maintains certified ISO9001 manufacturing facilities worldwide. Pall Life Sciences products for the biopharmaceutical industry include:

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

• Single-use technologies with Pall Allegro™ systems incorporating biocontainers, sterile connectors and disconnectors, sterile and tangential flow filtration capsules, disposable depth filters, and chromatography capsules • Capsules, cartridges, and housings for prefiltration, sterile filtration, virus reduction, and mycoplasma reduction • Tangential flow filtration products and systems • Chromatography sorbents, membrane devices, columns and systems • Depth filter products in wide selection of formats • Integrity test instrumentation • Bioreactor systems • Quality control instrumentation • Consulting, training, validation, and instrumentation services For additional information: www.pall.com/biopharm | pallindiamarketing@pall.com

EX H I B I TOR S APPLIKON BIOTECHNOLOGY is a world leader in developing and supplying advanced bioreactor systems from laboratory scale to production scale. We are the only company that can take a customer from the initial screening stage up to full-scale production using the same platform. This minimizes scale-up risks and guarantees the shortest time to market for our customers' new product development. Applikon is known for bringing new technologies to the market. These new technologies offer advantages in process efficiency for research and development as well as pilot plant and production scale processes. As a focused medium sized company we live by our motto "A Step Ahead" to differentiate ourselves from other suppliers. Our focus on developing bioreactor systems only, allows us to produce state-of-the-art equipment. This has resulted in a steady growth to the top position of the worldwide laboratory bioreactor market. The basis for our new product development lies in our strong cooperation with leading international universities and institutes. ……… HIMEDIA possesses world-class hi-tech knowhow for manufacturing a complete range of chromogenic and HiVeg™ media products. We have the broadest range of Vegetable Hydrolysate based microbiology culture media (HiVeg™), in the world. This is due to our vertically integrated manufacturing that produces a comprehensive range of Plant and Animal based hydrolysates. Advanced products in the fields of Animal Cell Culture, Plant Tissue Culture and Molecular Biology came next as demands grew. An excellent chemical testing facility equipped with the latest analytical instruments enables HiMedia to deliver consistent ultra-pure products.

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

……… KERRY 是全球蛋白質水解物,酵母抽出物及細胞營

養添加劑的主要供應廠商, 也是全球唯一同時擁有酵母粉和蛋白腖生產線的傑出企業, 全集團以高品質的產品服務全球細胞培養生物製藥發酵,疫苗,診斷及傳統發酵行業已近 70 年 . For more than 70 years, we have earned our reputation for reliability and excellence in serving the biotech, pharmaceutical and fermentation markets by delivering unsurpassed product value, enhanced opportunities for supply chain consolidation, and new technology innovation. ………

甘肃健顺生物科技有限公司致力于“无血清个性化化学成份界定细胞培养基”及其工艺的研究开发。产品主要应用于生物制药（治疗性重组蛋白，包括单克隆抗体）、细胞治疗以及人/兽用疫苗的工艺开发与生产。公司已通过 ISO9001 质量管理体系和 ISO14001 环境管理体系的认证。公司引进国内外一流设备和高端人才，拥有年产细胞培养基 300 吨的工业化生产的产业规模。细胞培养基是生物制药的关键原材料，公司将持续为海内外生物制药行业提供世界一流的细胞培养基及工艺开发、技术支持与一站式配套服务。 JIANSHUN BIOSCIENCES CO., LTD. is committed to developing and manufacturing “customized serum-free, chemically-defined cell culture medium”, and focuses on development and research of bioprocess and technology. JS Bio’s cell culture media are mainly applied in biopharmaceutical manufacturing (therapeutic recombinant proteins, including monoclonal antibody), cell therapy, and human/animal vaccines’ manufacturing and bioprocess development. JS Bio has passed ISO9001 Quality Management System and ISO14001 Environmental Management System Certification. JS Bio is equipped with world-class experts and facilities, with an annual output of 300 tons of cell culture media industry scale. Cell culture medium is the key raw material in biopharmaceutical manufacturing, JS Bio has the responsibility and confidence to work for the well-being of the world of human by producing the highest quality cell culture medium, process development and one-stop service for the biopharmaceutical industry. Add: 甘肃省兰州市安宁区九州通西路 70 号（新城科技孵化大厦 B 塔） Tower B, Incubator Building, No70, Jiuzhoutong West Rd., Anning District, Lanzhou, GanSu, China Tel: +86-931-7711111 | Fax: +86-931-7706500 E-mail: sales@jianshunbio.com | Web: www.jianshunbio.com ………

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

KRISHGEN BIOSYSTEMS is a leading manufacturer & supplier of tools for Drug Discovery Research, Biopharmaceutical industry, plant & food sciences. As pioneers for offering tools for the Biosimilar and Vaccine manufacturers, we have built expertise to offer a range of solutions for both upstream, downstream, in-process and QC. We are also ISO 9001 2008 certified and D&B SMERA rated company. We work with our parent company Krishgen BioSystems; USA and offer products that are exported to leading users based in USA, Europe & Asia. www.krishgen.com ……… LAMBDA THERAPEUTIC RESEARCH LIMITED is a leading global Clinical Research Organization (CRO) headquartered in Ahmedabad - India, with facilities and operations in Mumbai, Toronto (Canada), Warsaw (Poland), London (UK) and USA. Lambda offers full spectrum clinical trial solutions empowered by more than 14 years of service to the biopharmaceutical and generic industry. Lambda's core strengths Global presence with capabilities in Indian subcontinent, Europe and North America Global team comprising of professionals equipped with full lifecycle Clinical Trial Management expertise Huge investigator database Customised solutions for special population studies More than 1,50,000 active study participants in its global database More than 700 validated LC/MS - MS assays available globally Over 50 successful regulatory audits and inspections globally More than 40 LC-MS/MS systems CAP accredited Clinical, Molecular and Microbiological laboratory Conduct QT studies with replicate ECGs and ECG Core Laboratory Low temperature storage (2-8 °C, -20 °C and -80 °C) controlled storage facility to store over 3.5 million samples Adverse Event Safety Database State-of-the-art Medical Imaging Solutions EDC (paperless execution) of both BA-BE & clinical trials through means of a 21 CFR Part 11 compliant & indigenously developed validated software 'BizNet' ……… As a leading-edge company in the development of bio-agricultural technology, HEALTHGEN BIOTECHNOLOGY has innovated one of the

VACCINE WORLD SUMMIT INDIA 2015 CONFERENCE PROCEEDINGS http://www.imapac.com/business_conference/vwsi2015/

most expressive bioreactors OryzHiExp, which can highly express proteins and small peptides in cereal crop endosperm. We had successfully developed comprehensive products, including rHSA(recombinant human serum albumin), rbFGF (recombinant human basic fibroblast growth factor), LF (recombinant lactoferrin), IGF-1 (recombinant Insulin-like Growth Factor-1) and rAAT (recombinant human a1 antitrypsin). All the recombinant components can optimize cell culture, stimulate growth and protein productivity and shorten downstream process development. Meanwhile we are experiencing cooperation with other prospective biotechnology and pharmaceutical companies in expressing their ideal proteins or peptides. ……… SIGMA-ALDRICH is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. SigmaAldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 37 countries and has more than 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovative products, customized solutions and unsurpassed service. Our mission is to enable science to improve the quality of life. ……… WEST works side-by-side with its healthcare partners from concept to the patient, designing and manufacturing packaging, diagnostic and delivery systems that promote the efficiency, reliability and safety of their drug products. West’s customers include the world’s leading pharmaceutical, biopharmaceutical and medical device companies. Every day, West is leading the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched and growing knowledge base of relevant pharmaceutical product testing, development and packaging. Based in Exton, Pa., West supports its customers from sales, manufacturing, customer support and research and development locations in North and South America, Europe, Asia and Australia. Established in 1923, West's 2012 sales totaled $1.3 billion.

Vaccine World CIS & CEE Summit (7 â&#x20AC;&#x201C; 8 November 2013)

IMAPAC PTE LTD 100 Beach Road #16-09 Shaw Tower Singapore 189702